Evaluating potential predictors of weight loss response to liraglutide in adolescents with obesity: A post hoc analysis of the randomized, placebo‐controlled SCALE Teens trial
Authors' conclusion
This secondary analysis suggests that adolescents with obesity may experience significant BMI reductions after 56 weeks of liraglutide treatment, regardless of their sex, race, ethnicity, age, pubertal stage, glycemic status, obesity category, severity of depression symptoms, or weight variability. Early response may predict greater week 56 response.
Study context
- Population
- Pubertal adolescents with obesity in the SCALE Teens trial
- Participants
- 251 adolescents
- Comparison
- Liraglutide 3.0 mg vs placebo; baseline predictors of body mass index (BMI) response
- Liraglutiden = 125
- Placebon = 126reference
- Primary endpoint
- Baseline characteristics predictive of achieving ≥5% and ≥10% BMI reductions with liraglutide vs placebo
- Follow-up
- 56 weeks
Methodological detailsplacebo-controlled, logistic regression
- Placebo-controlled
- Logistic regression
Primary result
As reported in the abstract
week 56
- Baseline characteristics (sex, race, ethnicity, age, Tanner stage, glycemic status, obesity category, depression symptom severity) did not affect achievement of ≥5% and ≥10% BMI reductions with liraglutide
- No association between weight variability and BMI reduction
Further findings
Early responder status (≥4% BMI reduction at week 16) and week 56 response
- Early liraglutide responders appeared to have greater BMI and body weight reductions at week 56 vs early non-responders
- Descriptive statistics
Original publication
Evaluating potential predictors of weight loss response to liraglutide in adolescents with obesity: A post hoc analysis of the randomized, placebo‐controlled SCALE Teens trial. Pediatr Obes. Published 1 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →